Johnson & Johnson CEO: U.S. Edge in Innovation Begins with Healthcare

(SeaPRwire) –   Over the past century, American innovation has revolutionized healthcare, transforming once-unthinkable concepts into life-saving solutions for patients worldwide.

As the United States nears its 250th anniversary, this legacy continues to evolve and grow stronger.

After decades at the intersection of science, manufacturing, and patient care, I witness daily that America’s capacity for innovation is not diminishing—it is accelerating.

What truly distinguishes the United States is not just its ability to invent, but its power to translate breakthrough discoveries into tangible real-world impact. Today, the U.S. leads the world in biopharmaceutical innovation, with American companies accounting for 55% of global research and development (R&D) and producing more new medicines than any other nation. This leadership directly benefits patients: approximately 70% of new medicines are launched first in the U.S., giving Americans earlier access—often months or even years sooner—than people in other countries.

We are now entering an era where scientific breakthroughs move rapidly from laboratory to patient bedside. Diseases are being detected earlier, treatments are becoming more personalized, and high-quality care is reaching more individuals than ever before. Progress today is measured not only by what we discover, but by how quickly and effectively we apply those discoveries.

And this progress is already transforming lives.

In cardiovascular care, American innovation is providing critically ill patients with precious additional time—time to recover, return home, and live fuller lives. In cancer treatment, innovation has dramatically shifted the outlook: diseases once deemed fatal are now increasingly manageable, and in some cases potentially curable, as science harnesses the body’s own biological systems as powerful weapons against disease.

Artificial intelligence is further accelerating this momentum, and once again, the U.S. leads the way.

AI is revolutionizing how our scientists develop medicines, design clinical trials, and match therapies to the patients who will benefit most. Research timelines that once took decades can now be compressed into years, while health systems are using limited expertise more efficiently than ever before.

However, AI will not replace the human element of healthcare. Instead, it will enhance human decision-making by automating routine tasks, allowing clinicians to spend more time listening to patients and delivering the most informed, compassionate care possible.

Innovation also extends into surgical settings, where advanced technologies are amplifying surgeons’ precision, delivering real-time insights to support better decisions and improved patient outcomes.

Yet, innovation alone cannot ensure better or longer lives.

Breakthroughs only matter if they reach those who need them. Guaranteeing access and affordability is not separate from innovation—it is central to its purpose. We must address current patient needs while continuing to invest in the advances that will define the next generation of care.

This balance is challenging. Many of today’s most transformative therapies were developed over years before reaching their first patients. At the same time, healthcare systems face genuine cost pressures, and patients require solutions that are both innovative and affordable. Meeting these dual challenges demands collaboration, scale, and a long-term vision.

Once again, America’s strengths shine through.

The United States uniquely brings together the institutions, manufacturing capabilities, and innovation ecosystems necessary to deliver breakthroughs at scale—supported by policies that value innovation, investment, and patients. This foundation explains why healthcare companies are deepening their commitment to the U.S.

Across the industry, hundreds of billions of dollars are being invested in American research and manufacturing. Johnson & Johnson alone has committed more than $55 billion over the next four years to expand U.S. R&D, manufacturing, and technology, building state-of-the-art facilities and ensuring that the vast majority of our most advanced medicines are produced domestically.

Healthcare represents a uniquely powerful form of investment—one that is both deeply human and economically vital. Numerous studies consistently show that every dollar invested in healthcare generates multiple times its value in economic returns. Health is not merely a cost to manage; it is a strategic investment in longer lives, stronger communities, and a more resilient economy.

Looking ahead toward America’s 250th year, true leadership will be defined by our ability to convert innovation into lasting value for both individuals and society. To me, that means investing in the one innovation that serves us all: the health of humanity.